\-\ Texto\\:\\ \ \(0\)\
\-\ bitemporal\\ hemianopsia\\ noted\ \(0\)\
\-\ radiation\\ therapy\ \(165\)\
\-\ \\â\\€\\¢\\ isointense\\ enhancing\\ hypothalamic\\ mass\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ tumor\\ extending\\ along\\ the\\ ependymal\\ surfaces\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ tumor\\ right\\ basal\\ ganglia\\ and\\ \\ corpus\\ callosum\\.\ \(0\)\
\-\ germinoma\\,\\ primary\\ intracranial\ \(0\)\
\-\ \\â\\€\\¢\\ craniopharyngioma\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\\,\\ lymphoma\ \(0\)\
\-\ \\â\\€\\¢\\ ependymoma\ \(8\)\
\-\ \\â\\€\\¢\\ langerhan\\ histiocytosis\ \(0\)\
\-\ \\â\\€\\¢\\ germinioma\ \(0\)\
\-\ \\â\\€\\¢\\ trilateral\\ retinoblastoma\ \(0\)\
\-\ 34\\ year\\ old\\ man\\ presents\\ with\\ signs\\ and\\ symptoms\\ of\\ hypo\\-thyroidism\\ and\\ evidence\\ of\\ pituitary\\ dysfunction\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.21368377521762105\ \(0\)\
\-\ germinioma\\:\\ 0\\.13356846096918937\ \(0\)\
\-\ trilateral\\:\\ 0\\.13356846096918937\ \(0\)\
\-\ hypo\\-thyroidism\\:\\ 0\\.13356846096918937\ \(0\)\
\-\ enhancing\\:\\ 0\\.12181606967657997\ \(0\)\
\-\ ependymal\\:\\ 0\\.09591836021482572\ \(0\)\
\-\ bitemporal\\:\\ 0\\.09155954093525329\ \(0\)\
\-\ germinoma\\:\\ 0\\.09155954093525329\ \(0\)\
\-\ langerhan\\:\\ 0\\.0906409860592467\ \(0\)\
\-\ retinoblastoma\\:\\ 0\\.08895574916363724\ \(0\)\
\-\ hemianopsia\\:\\ 0\\.08673448440315427\ \(0\)\
\-\ hypothalamic\\:\\ 0\\.0854161302063417\ \(0\)\
\-\ surfaces\\:\\ 0\\.08420336190825782\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.07204659717303151\ \(0\)\
\-\ dysfunction\\:\\ 0\\.06898240222613913\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.0685614997396683\ \(0\)\
\-\ callosum\\:\\ 0\\.06643487310792703\ \(0\)\
\-\ ganglia\\:\\ 0\\.06625556314357851\ \(0\)\
\-\ pituitary\\:\\ 0\\.0648927110729279\ \(0\)\
\-\ 34\\:\\ 0\\.06425465826459266\ \(0\)\
\-\ corpus\\:\\ 0\\.06379315512088495\ \(0\)\
\-\ isointense\\:\\ 0\\.06364239253220058\ \(0\)\
\-\ tumor\\:\\ 0\\.06037067580638822\ \(0\)\
\-\ basal\\:\\ 0\\.05902329542633899\ \(0\)\
\-\ ependymoma\\:\\ 0\\.057955846017996394\ \(0\)\
\-\ intracranial\\:\\ 0\\.054719874801359134\ \(0\)\
\-\ signs\\:\\ 0\\.04556630203009174\ \(0\)\
\-\ extending\\:\\ 0\\.04352604619454238\ \(0\)\
\-\ along\\:\\ 0\\.04278869510391691\ \(0\)\
\-\ radiation\\:\\ 0\\.04248865529639904\ \(0\)\
\-\ primary\\:\\ 0\\.038354307013571155\ \(0\)\
\-\ lymphoma\\:\\ 0\\.03700300961196191\ \(0\)\
\-\ therapy\\:\\ 0\\.034615769640009286\ \(0\)\
\-\ evidence\\:\\ 0\\.033946099747982995\ \(0\)\
\-\ metastatic\\:\\ 0\\.03259256672145591\ \(0\)\
\-\ symptoms\\:\\ 0\\.03226753752875969\ \(0\)\
\-\ noted\\:\\ 0\\.0306881998250393\ \(0\)\
\-\ man\\:\\ 0\\.030620179440757563\ \(0\)\
\-\ presents\\:\\ 0\\.026449155992544333\ \(0\)\
\-\ disease\\:\\ 0\\.02116269001841976\ \(0\)\
\-\ mass\\:\\ 0\\.018006984953750978\ \(0\)\
\-\ year\\:\\ 0\\.014486443473832041\ \(0\)\
\-\ right\\:\\ 0\\.01366108650167298\ \(0\)\
\-\ old\\:\\ 0\\.013256584800943253\ \(0\)\
\-\ \\,\\:\\ 0\\.008203335318705679\ \(0\)\
\-\ and\\:\\ 0\\.008182227533282658\ \(0\)\
\-\ of\\:\\ 0\\.0035304182059996496\ \(0\)\
\-\ the\\:\\ 0\\.002094686131873118\ \(0\)\
\-\ with\\:\\ 0\\.0017727905468165111\ \(0\)\
\-\ \\.\\:\\ 0\\.0010757435181014024\ \(0\)\
